[Fluorescein angiography in diabetic retinopathy (author's transl)].

A. Alezzandrini

Acta Diabetologica Latina

Abstract:

What problem does this paper attempt to address?

Usability of the Mayo Test Drive remote self-administered web-based cognitive screening battery in adults ages 35 to 100 with and without cognitive impairment

Jay S Patel,Teresa J Christianson,Logan T Monahan,Ryan D Frank,Winnie Z Fan,John L Stricker,Walter K Kremers,Aimee J Karstens,Mary M Machulda,Julie A Fields,Jason Hassenstab,Clifford R. Jack Jr.,Hugo Botha,Jonathan Graff-Radford,Ronald C Petersen,Nikki Horne Stricker

DOI: https://doi.org/10.1101/2024.05.24.24307909

2024-05-28

Abstract:Background. Self-administered cognitive screening measures that can be completed unsupervised and remotely have significant promise for high scalability. Mayo Test Drive (MTD): Test Development through Rapid Iteration, Validation and Expansion, is a web-based remote cognitive assessment platform for self-administered neuropsychological measures with previously demonstrated validity and reliability. Our primary study aim was to examine the usability of MTD. We additionally described participation and adherence rates; characterized factors that inform feasibility to implement MTD in research and clinical settings such as session and subtest durations, frequency of interruptions and noise during test sessions, device type use across demographic and clinical characteristics for completed sessions; and reported qualitative themes of free-text participant comments. Methods. 1,950 Mayo Clinic Study of Aging and Mayo Alzheimer Disease Research Center participants (97% White, 99% Non-Hispanic) were invited to participate in this ancillary, uncompensated remote study. Most invitees were cognitively unimpaired (CU; n=1,769; 90.7%) and 9.3% were cognitively impaired (CI; n=181). Participation and adherence rates were defined as the number of participants initiating a test session when invited or due to complete a session, respectively. Usability was objectively defined as the percentage of participants who completed a session after initiating a session for a given timepoint (i.e., completion rates). MTD sessions included the Stricker Learning Span (SLS) learning and delay trials, four trials of the Symbols test, and completion of self-report questions that informed session context. All participants were invited to provide free-text comments that were coded by investigators and descriptively characterized by qualitative analysis. Results. Baseline session completion rates were 98.5% across participants who initiated a test session (n=1199/1217, mean age 71, SD=12, range 35-100) and were comparable between CU (98.7%) and CI (95.0%) groups (p=.23). Completion rates did not significantly differ by age groups among CU participants (p>.10) and completion rates remained high in individuals 80+ (n=251, 97.3%). Participation rates were higher in the CU (n=1142, 65.4%) versus CI (n=57, 33.1%) group (p<.001). Participation rates were lower in those 80+ (53.8%) relative to younger age groups (68.9% ages 34-64; 70.2% ages 65-69). Adherence (i.e., retention) rate for a 7.5-month follow-up session was 89%. Average session duration was 16 minutes. Most participants used a personal computer (n=751, 62.7%), followed by a smartphone (n=266, 22.2%) or tablet (n=177, 14.8%). Comments were entered by 36.4% of participants and reflected several themes relevant to acceptability, face validity, usability, as well as comments informative for session context. Conclusions. MTD demonstrated high usability as defined by completion rates in this research sample that includes a broad age range, though participation rates are lower in individuals with cognitive impairment. Results support good adherence at follow-up, feasibility through mean session durations, and acceptability based on qualitative analysis of participant comments.
The development and validation of a digital biomarker for remote assessment of Alzheimer's diseases risk

Joe Butler,Tamlyn J Watermeyer,Ellie Matterson,Emily G Harper,Mario Parra-Rodriguez

DOI: https://doi.org/10.1177/20552076241228416

2024-01-01

Digital Health

Abstract:Background Digital cognitive assessment is becoming increasingly widespread in ageing research and care, especially since the COVID-19 pandemic. Remote online collection provides opportunities for ageing and dementia professionals to collect larger datasets, increase the diversity of research participants and patients and offer cost-effective screening and monitoring methods for clinical practice and trials. However, the reliability of self-administered at-home tests compared to their lab-based counterparts often goes unexamined, compromising the validity of adopting such measures. Objective Our aim is to validate a self-administered web-based version of the visual short-term memory binding task (VSTMBT), a potential digital biomarker sensitive to Alzheimer's disease processes, suitable for use on personal devices. Methods A final cross-sectional sample of 37 older-adult (51–77 years) participants without dementia completed our novel self-administered version of the VSTMBT, both at home on a personal device and in the lab, under researcher-controlled conditions. Results ANOVA and Bayesian t-test found no significant differences between the task when it was remotely self-administered by participants at home compared to when it was taken under controlled lab conditions. Conclusions These results indicate the VSTMBT can provide reliable data when self-administered at-home using an online version of the task and on a personal device. This finding has important implications for remote screening and monitoring practices of older adults, as well as supporting clinical practices serving diverse patient communities. Future work will assess remote administration in older adults with cognitive impairment and diverse socio-economic and ethno-cultural backgrounds as well as a bench-to-bedside application.

public, environmental & occupational health,health care sciences & services,medical informatics,health policy & services
Examining a Preclinical Alzheimer's Cognitive Composite for Telehealth Administration for Reliability Between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers

Tugce Duran,Sarah A. Gaussoin,Lauren A. Latham,Melissa M. Rundle,Mark A. Espeland,Benjamin J. Williams,Timothy M. Hughes,Suzanne Craft,Bonnie C. Sachs,James R. Bateman,Samuel N. Lockhart

DOI: https://doi.org/10.3233/jad-231435

2024-04-27

Journal of Alzheimer s Disease

Abstract:Background: The preclinical Alzheimer's cognitive composite (PACC) was developed for in-person administration to capture subtle cognitive decline. At the outset of the COVID-19 pandemic, cognitive testing was increasingly performed remotely by telephone or video administration. It is desirable to have a harmonized composite measurement derived from both in-person and remote assessments for identifying cognitive changes and to examine its relationship with common neuroimaging biomarkers. Objective: We defined a telehealth compatible PACC (tPACC) and examined its relationship with neuroimaging biomarkers related to neurodegeneration, brain function and perfusion, white matter integrity, and amyloid-β. Methods: We examined 648 participants' neuroimaging and in-person and remote cognitive testing data from the Wake Forest Alzheimer's Disease Research Center's Clinical Core cohort (observational study) to calculate a modified PACC (PACC5-RAVLT) score and tPACC scores (in-person and remote). We performed Spearman/intraclass correlation coefficient (ICC) analyses for reliability of tPACC scores and linear regression models to evaluate associations between tPACC and neuroimaging. Bland-Altman plots for agreement were constructed across cognitively normal and impaired (mild cognitive impairment and dementia) participants. Results: There was a significant positive relationship between tPACCin - person and PACC5-RAVLT (Overall group: r2 = 0.94, N = 648), and tPACCin - person and tPACCremote (validation subgroup: ICC = 0.82, n = 53). Overall, tPACC showed significant associations with brain thickness/volume, gray matter perfusion, white matter free water, and amyloid-β deposition. Conclusions: There is a good agreement between tPACCand PACC5-RAVLTfor cognitively normal and impaired individuals. The tPACC is associated with common neuroimaging markers of Alzheimer's disease.

neurosciences
98 Remote App-Based Assessment of Memory and Executive Functioning in Aging and Pre-Clinical Alzheimer’s Disease

Dawn Mechanic-Hamilton,Kimberly Halberstadter,MIchael Dicalogero,Rachel Rovere,La’cendria Pulley,David Wolk

DOI: https://doi.org/10.1017/s135561772300958x

2023-11-01

Journal of the International Neuropsychological Society

Abstract:Objective: Mobile, valid, and engaging cognitive assessments are essential for detecting and tracking change in research participants and patients at risk for Alzheimer’s Disease and Related Dementias (ADRDs). This pilot study aims to determine the feasibility and performance of app-based memory and executive functioning tasks included in the mobile cognitive app performance platform (mCAPP), to remotely detect cognitive changes associated with aging and preclinical Alzheimer’s Disease (AD). Participants and Methods: The mCAPP includes three gamified tasks: (1) a memory task that includes learning and matching hidden card pairs and incorporates increasing memory load, pattern separation features (lure vs. non-lure), and spatial memory (2) a stroop-like task (“brick drop”) with speeded word and color identification and response inhibition components and (3) a digit-symbol coding-like task (“space imposters”) with increasing pairs and incidental learning components. The cohort completed the NACC UDS3 neuropsychological battery, selected NIH Toolbox tasks, and additional cognitive testing sensitive to pre-clinical AD, within six months of the mCAPP testing. Participants included thirty-seven older adults (60% female; age=72±4.4, years of education=17±2.5; 67% Caucasian, 30% Black/AA, 3% Multiracial) with normal cognition who are enrolled in the Penn Alzheimer’s Disease Research Center (ADRC) cohort. Participants completed one in-person session and two weeks of at-home testing, with eight scheduled sessions, four in the morning and four in the afternoon. Participants also completed questionnaires and an interview about technology use and wore activity trackers to collect daily step and sleep data and answered questions about mood, anxiety, and fatigue throughout the two weeks of at-home data collection. Results: The participants completed an average of 11 at-home sessions, with the majority choosing to play extra sessions. Participants reported high usability ratings for all tasks and the majority rated the task difficulty as acceptable. On all mCAPP tasks, participant performance declined in accuracy and speed with increasing memory load and task complexity. mCAPP tasks correlated significantly with paper and pencil measures and several NIH Toolbox tasks (p<0.05). Examination of performance trends over multiple sessions indicates stabilization of performance within 4-6 sessions on memory mCAPP measures and 5-7 sessions on executive functioning mCAPP measures. Preliminary analyses indicate differences in mCAPP measures and imaging biomarkers. Conclusions: Participants were willing and able to complete at-home cognitive testing and most chose to complete more than the assigned sessions. Remote data collection is feasible and well-tolerated. We show preliminary construct validity with the UDS3 and NIH Toolbox and test-retest reliability following a period of task learning and performance improvement and stabilization. This work will help to advance remote detection and monitoring of early cognitive changes associated with preclinical AD. Future directions will include further evaluation of the relationships between mCAPP performance, behavioral states, and neuroimaging biomarkers as well as the utility of detection of practice effects in identifying longitudinal change and risk for ADRD-related cognitive decline.

psychology,clinical neurology,psychiatry,neurosciences
Seeing beyond the symptoms: biomarkers and brain regions linked to cognitive decline in Alzheimer's disease

Seyed Hani Hojjati,Abbas Babajani-Feremi,for the Alzheimer's Disease Neuroimaging Initiative

DOI: https://doi.org/10.3389/fnagi.2024.1356656

IF: 4.8

2024-05-16

Frontiers in Aging Neuroscience

Abstract:Objective: Early Alzheimer's disease (AD) diagnosis remains challenging, necessitating specific biomarkers for timely detection. This study aimed to identify such biomarkers and explore their associations with cognitive decline. Methods: A cohort of 1759 individuals across cognitive aging stages, including healthy controls (HC), mild cognitive impairment (MCI), and AD, was examined. Utilizing nine biomarkers from structural MRI (sMRI), diffusion tensor imaging (DTI), and positron emission tomography (PET), predictions were made for Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale Sum of Boxes (CDRSB), and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS). Biomarkers included four sMRI (e.g., average thickness [ATH]), four DTI (e.g., mean diffusivity [MD]), and one PET Amyloid-β (Aβ) measure. Ensemble regression tree (ERT) technique with bagging and random forest approaches were applied in four groups (HC/MCI, HC/AD, MCI/AD, and HC/MCI/AD). Results: Aβ emerged as a robust predictor of cognitive scores, particularly in late-stage AD. Volumetric measures, notably ATH, consistently correlated with cognitive scores across early and late disease stages. Additionally, ADAS demonstrated links to various neuroimaging biomarkers in all subject groups, highlighting its efficacy in monitoring brain changes throughout disease progression. ERT identified key brain regions associated with cognitive scores, such as the right transverse temporal region for Aβ, left and right entorhinal cortex, left inferior temporal gyrus, and left middle temporal gyrus for ATH, and the left uncinate fasciculus for MD. Conclusion: This study underscores the importance of an interdisciplinary approach in understanding AD mechanisms, offering potential contributions to early biomarker development.

neurosciences,geriatrics & gerontology,gerontology
Validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study

Caroline Skirrow,Marton Meszaros,Udeepa Meepegama,Raphael Lenain,Kathryn V Papp,Jack Weston,Emil Fristed

DOI: https://doi.org/10.2196/37090

2022-09-30

JMIR Aging

Abstract:Background: Story recall is a simple and sensitive cognitive test that is commonly used to measure changes in episodic memory function in early Alzheimer disease (AD). Recent advances in digital technology and natural language processing methods make this test a candidate for automated administration and scoring. Multiple parallel test stimuli are required for higher-frequency disease monitoring. Objective: This study aims to develop and validate a remote and fully automated story recall task, suitable for longitudinal assessment, in a population of older adults with and without mild cognitive impairment (MCI) or mild AD. Methods: The "Amyloid Prediction in Early Stage Alzheimer's disease" (AMYPRED) studies recruited participants in the United Kingdom (AMYPRED-UK: NCT04828122) and the United States (AMYPRED-US: NCT04928976). Participants were asked to complete optional daily self-administered assessments remotely on their smart devices over 7 to 8 days. Assessments included immediate and delayed recall of 3 stories from the Automatic Story Recall Task (ASRT), a test with multiple parallel stimuli (18 short stories and 18 long stories) balanced for key linguistic and discourse metrics. Verbal responses were recorded and securely transferred from participants' personal devices and automatically transcribed and scored using text similarity metrics between the source text and retelling to derive a generalized match score. Group differences in adherence and task performance were examined using logistic and linear mixed models, respectively. Correlational analysis examined parallel-forms reliability of ASRTs and convergent validity with cognitive tests (Logical Memory Test and Preclinical Alzheimer's Cognitive Composite with semantic processing). Acceptability and usability data were obtained using a remotely administered questionnaire. Results: Of the 200 participants recruited in the AMYPRED studies, 151 (75.5%)-78 cognitively unimpaired (CU) and 73 MCI or mild AD-engaged in optional remote assessments. Adherence to daily assessment was moderate and did not decline over time but was higher in CU participants (ASRTs were completed each day by 73/106, 68.9% participants with MCI or mild AD and 78/94, 83% CU participants). Participants reported favorable task usability: infrequent technical problems, easy use of the app, and a broad interest in the tasks. Task performance improved modestly across the week and was better for immediate recall. The generalized match scores were lower in participants with MCI or mild AD (Cohen d=1.54). Parallel-forms reliability of ASRT stories was moderate to strong for immediate recall (mean rho 0.73, range 0.56-0.88) and delayed recall (mean rho=0.73, range=0.54-0.86). The ASRTs showed moderate convergent validity with established cognitive tests. Conclusions: The unsupervised, self-administered ASRT task is sensitive to cognitive impairments in MCI and mild AD. The task showed good usability, high parallel-forms reliability, and high convergent validity with established cognitive tests. Remote, low-cost, low-burden, and automatically scored speech assessments could support diagnostic screening, health care, and treatment monitoring.
Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease

Kevin Duff,Dustin B. Hammers,Vincent Koppelmans,Jace B. King,John M. Hoffman

DOI: https://doi.org/10.3233/jad-231392

2024-04-24

Journal of Alzheimer s Disease

Abstract:Background: Practice effects on cognitive testing in mild cognitive impairment (MCI) and Alzheimer's disease (AD) remain understudied, especially with how they compare to biomarkers of AD. Objective: The current study sought to add to this growing literature. Methods: Cognitively intact older adults (n = 68), those with amnestic MCI (n = 52), and those with mild AD (n = 45) completed a brief battery of cognitive tests at baseline and again after one week, and they also completed a baseline amyloid PET scan, a baseline MRI, and a baseline blood draw to obtain APOE ɛ4 status. Results: The intact participants showed significantly larger baseline cognitive scores and practice effects than the other two groups on overall composite measures. Those with MCI showed significantly larger baseline scores and practice effects than AD participants on the composite. For amyloid deposition, the intact participants had significantly less tracer uptake, whereas MCI and AD participants were comparable. For total hippocampal volumes, all three groups were significantly different in the expected direction (intact > MCI > AD). For APOE ɛ4, the intact had significantly fewer copies of ɛ4 than MCI and AD. The effect sizes of the baseline cognitive scores and practice effects were comparable, and they were significantly larger than effect sizes of biomarkers in 7 of the 9 comparisons. Conclusion: Baseline cognition and short-term practice effects appear to be sensitive markers in late life cognitive disorders, as they separated groups better than commonly-used biomarkers in AD. Further development of baseline cognition and short-term practice effects as tools for clinical diagnosis, prognostic indication, and enrichment of clinical trials seems warranted.

neurosciences
Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers

Weineng Chen,Cha Lin,Fengjuan Su,Yingying Fang,Ganqiang Liu,Yu-Chian Chen,Xianbo Zhou,Xiaoli Yao,Curtis B Ashford,Feng Li,J Wesson Ashford,Qing-Ling Fu,Zhong Pei

DOI: https://doi.org/10.3233/JAD-230182

Abstract:Background: Accessible measurements for the early detection of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) are urgently needed to address the increasing prevalence of AD. Objective: To determine the benefits of a composite MemTrax Memory Test and AD-related blood biomarker assessment for the early detection of MCI-AD in non-specialty clinics. Methods: The MemTrax Memory Test and Montreal Cognitive Assessment were administered to 99 healthy seniors with normal cognitive function and 101 patients with MCI-AD; clinical manifestation and peripheral blood samples were collected. We evaluated correlations between the MemTrax Memory Test and blood biomarkers using Spearman's rank correlation analyses and then built discrimination models using various machine learning approaches that combined the MemTrax Memory Test and blood biomarker results. The models' performances were assessed according to the areas under the receiver operating characteristic curve. Results: The MemTrax Memory Test and Montreal Cognitive Assessment areas under the curve for differentiating patients with MCI-AD from the healthy controls were similar. The MemTrax Memory Test strongly correlated with phosphorylated tau 181 and amyloid-β42/40. The area under the curve for the best composite MemTrax Memory Test and blood biomarker model was 0.975 (95% confidence interval: 0.950-0.999). Conclusion: Combining MemTrax Memory Test and blood biomarker results is a promising new technique for the early detection of MCI-AD.
Digital cognitive assessments as low‐burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum

Casey R. Vanderlip,Craig E. L. Stark,for the Alzheimer's Disease Neuroimaging Initiative

DOI: https://doi.org/10.1002/alz.14154

2024-09-08

Alzheimer s & Dementia

Abstract:BACKGROUND Digital cognitive assessments, particularly those that can be done at home, present as low‐burden biomarkers for participants and patients alike, but their effectiveness in the diagnosis of Alzheimer's disease (AD) or predicting its trajectory is still unclear. Here, we assessed what utility or added value these digital cognitive assessments provide for identifying those at high risk of cognitive decline. METHODS We analyzed >500 Alzheimer's Disease Neuroimaging Initiative participants who underwent a brief digital cognitive assessment and amyloid beta (Aβ)/tau positron emission tomography scans, examining their ability to distinguish cognitive status and predict cognitive decline. RESULTS Performance on the digital cognitive assessment was superior to both cortical Aβ and entorhinal tau in detecting mild cognitive impairment and future cognitive decline, with mnemonic discrimination deficits emerging as the most critical measure for predicting decline and future tau accumulation. DISCUSSION Digital assessments are effective at identifying at‐risk individuals, supporting their utility as low‐burden tools for early AD detection and monitoring. Highlights Performance on digital cognitive assessments predicts progression to mild cognitive impairment at a higher proficiency compared to amyloid beta and tau. Deficits in mnemonic discrimination are indicative of future cognitive decline. Impaired mnemonic discrimination predicts future entorhinal and inferior temporal tau.

clinical neurology
Association between a computerized, self-administered cognitive assessment and phosphorylated Tau in Alzheimer's Disease

Mina Aghaei,Zahra Vahabi,Mohammad Hadi Modarres,Fatemeh Ebrahiminia,Seyed-Mahdi Khaligh-Razavi

DOI: https://doi.org/10.1101/2024.11.23.24317846

2024-11-26

Abstract:Introduction: Alzheimer's Disease (AD) is the leading cause of dementia, accounting for 80% of cases globally. With an aging population, AD poses a growing concern due to its increasing mortality rate and associated healthcare costs. Early diagnosis or prediction of AD is crucial for managing and potentially slowing its progression, particularly with the advent of disease-modifying therapies. Methods: This study involved a total of 60 participants: 15 with mild AD, 23 with mild cognitive impairment (MCI), and 22 healthy controls, comprising both males and females aged 50-85 years. Data collection included blood samples, the Montreal Cognitive Assessment (MoCA), and the Integrated Cognitive Assessment (ICA). Serum phosphorylated tau181 (p-tau181) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. Linear regression models were applied to predict serum biomarker levels based on the ICA index, demographic data, and APOEϵ4 status. Aims and Objectives: The primary aim was to examine the association between ICA scores and blood-based p-tau181 levels in individual with MCI, mild AD, and elderly healthy controls. Additionally, the study compared the correlation of ICA and MoCA with APOEϵ4 status. Findings: The study found that the ICA can significantly differentiate between diagnostic groups and that elevated serum p-tau181 levels are associated with cognitive decline, as measured by the ICA. Additionally, a significant correlation was observed between APOEϵ4 status and cognitive decline, but not between APOEϵ4 status and serum p-tau181 levels. Using a model that incorporates the ICA, demographic data, and APOEϵ4 status, we were able to modestly predict serum p-tau181 levels, indicating the potential of combining cognitive assessment with biological markers for AD prediction. Discussion: The findings suggest that ICA is a valuable tool in detecting cognitive decline associated with AD and correlates with increased p-tau181 levels. The significant correlation between APOEϵ4 status and cognitive decline highlights its potential role in risk assessment, independent of p-tau181 levels. The study supports the use of a computerized, self-administered cognitive assessment in conjunction with blood-based biomarkers for early AD detection. Limitations include the small sample size and cross-sectional design, which restricts causal inference and longitudinal analysis. Future research should focus on larger, longitudinal studies to further validate these associations and their implications for early diagnosis and monitoring of AD progression.

Geriatric Medicine
Performance and validation of a digital memory test across the Alzheimer's Disease continuum

Sofia Toniolo,Bahaaeddin Attaallah,Maria Raquel Maio,Younes Adam Tabi,Elitsa Slavkova,Verena Svenja Klar,Youssuf Saleh,Mohamad Imran Idris,Vicky Turner,Christoph Preul,Annie Srowig,Christopher Butler,Sian Thompson,Sanjay G Manohar,Kathrin Finke,Masud Husain

DOI: https://doi.org/10.1101/2024.06.18.24309112

2024-06-19

Abstract:Digital cognitive testing using online platforms has emerged as a potentially transformative tool in clinical neuroscience. In theory, it could provide a powerful means of screening for and tracking cognitive performance in people at risk of developing conditions such as Alzheimer's Disease (AD). Here we investigate whether digital metrics derived from a tablet-based short- term memory task - 'What was where?'- Oxford Memory Task - were able to clinically stratify patients at different points within the AD continuum and to track disease progression over time. Performance of these metrics to traditional neuropsychological pen-and-paper screening tests of cognition was also analyzed. A total of 325 people participated in this study: 49 patients with subjective cognitive impairment (SCI), 57 with mild cognitive impairment (MCI), 63 with AD dementia and 156 elderly healthy controls (EHC). Most digital metrics were able to discriminate between healthy controls and patients with MCI and between MCI and AD patients. Some, including Absolute Localization Error, also differed significantly between patients with SCI and MCI. Identification accuracy was the best predictor of hippocampal atrophy, performing as well as standard screening neuropsychological tests. A linear support vector model combining digital metrics achieved high accuracy and performed at par with standard testing in discriminating between EHC and SCI (AUC 0.82) and between SCI and MCI (AUC 0.92). Memory imprecision was able to predict cognitive decline on standard cognitive tests over one year. Overall, these findings show how it might be possible to use a digital memory test in clinics and clinical trial contexts to stratify and track performance across the Alzheimer's disease continuum.

Neurology
Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer's disease

David Berron,Emil Olsson,Felix Andersson,Shorena Janelidze,Pontus Tideman,Emrah Düzel,Sebastian Palmqvist,Erik Stomrud,Oskar Hansson

DOI: https://doi.org/10.1002/alz.13919

2024-06-14

Alzheimer s & Dementia

Abstract:INTRODUCTION Remote unsupervised cognitive assessments have the potential to complement and facilitate cognitive assessment in clinical and research settings. METHODS Here, we evaluate the usability, validity, and reliability of unsupervised remote memory assessments via mobile devices in individuals without dementia from the Swedish BioFINDER‐2 study and explore their prognostic utility regarding future cognitive decline. RESULTS Usability was rated positively; remote memory assessments showed good construct validity with traditional neuropsychological assessments and were significantly associated with tau‐positron emission tomography and downstream magnetic resonance imaging measures. Memory performance at baseline was associated with future cognitive decline and prediction of future cognitive decline was further improved by combining remote digital memory assessments with plasma p‐tau217. Finally, retest reliability was moderate for a single assessment and good for an aggregate of two sessions. DISCUSSION Our results demonstrate that unsupervised digital memory assessments might be used for diagnosis and prognosis in Alzheimer's disease, potentially in combination with plasma biomarkers. Highlights Remote and unsupervised digital memory assessments are feasible in older adults and individuals in early stages of Alzheimer's disease. Digital memory assessments are associated with neuropsychological in‐clinic assessments, tau‐positron emission tomography and magnetic resonance imaging measures. Combination of digital memory assessments with plasma p‐tau217 holds promise for prognosis of future cognitive decline. Future validation in further independent, larger, and more diverse cohorts is needed to inform clinical implementation.

clinical neurology
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

Dawn C Matthews,Jefferson W Kinney,Aaron Ritter,Randolph D Andrews,Erin N Toledano Strom,Ana S Lukic,Lauren N Koenig,Carolyn Revta,Howard M Fillit,Kate Zhong,Babak Tousi,James B Leverenz,Howard H Feldman,Jeffrey Cummings

DOI: https://doi.org/10.1002/trc2.12490

2024-07-09

Abstract:Introduction: The "A/T/N" (amyloid/tau/neurodegeneration) framework provides a biological basis for Alzheimer's disease (AD) diagnosis and can encompass additional changes such as inflammation ("I"). A spectrum of T/N/I imaging and plasma biomarkers was acquired in a phase 2 clinical trial of rasagiline in mild to moderate AD patients. We evaluated these to understand biomarker distributions and relationships within this population. Methods: Plasma biomarkers of pTau-181, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), other inflammation-related proteins, imaging measures including fluorodeoxyglucose (FDG) positron emission tomography (PET), flortaucipir PET, and volumetric magnetic resonance imaging (MRI), and cognitive endpoints were analyzed to assess characteristics and relationships for the overall population (N = 47 at baseline and N = 21 for longitudinal cognitive comparisons) and within age-decade subgroups (57-69, 70-79, 80-90 years). Results: Data demonstrate wide clinical and biomarker heterogeneity in this population influenced by age and sex. Plasma pTau-181 and GFAP correlate with tau PET, most strongly in left inferior temporal cortex (p = 0.0002, p = 0.0006, respectively). In regions beyond temporal cortex, tau PET uptake decreased with age for the same pTau-181 or GFAP concentrations. FDG PET and brain volumes correlate with tau PET in numerous regions (such as inferior temporal: p = 0.0007, p = 0.00001, respectively). NfL, GFAP, and all imaging modalities correlate with baseline MMSE; subsequent MMSE decline is predicted by baseline parahippocampal and lateral temporal tau PET (p = 0.0007) and volume (p = 0.0006). Lateral temporal FDG PET (p = 0.006) and volume (p = 0.0001) are most strongly associated with subsequent ADAS-cog decline. NfL correlates with FDG PET and baseline MMSE but not tau PET. Inflammation biomarkers are intercorrelated but correlated with other biomarkers in only the youngest group. Discussion: Associations between plasma biomarkers, imaging biomarkers, and cognitive status observed in this study provide insight into relationships among biological processes in mild to moderate AD. Findings show the potential to characterize AD patients regarding likely tau pathology, neurodegeneration, prospective clinical decline, and the importance of covariates such as age. Highlights: Plasma pTau-181 and GFAP correlated with regional and global tau PET in mild to moderate AD.NfL correlated with FDG PET and cognitive endpoints but not plasma pTau-181 or tau PET.Volume and FDG PET showed strong relationships to tau PET, one another, and cognitive status.Temporal volumes most strongly predicted decline in both MMSE and ADAS-cog.Volume and plasma biomarkers can enrich for elevated tau PET with age a significant covariate.
Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum

Casey R. Vanderlip,Craig E.L. Stark

DOI: https://doi.org/10.1101/2024.05.23.595638

2024-05-26

Abstract:Digital cognitive assessments, particularly those that can be done at home, present as low burden biomarkers for participants and patients alike, but their effectiveness in diagnosis of Alzheimer's or predicting its trajectory is still unclear. Here, we assessed what utility or added value these digital cognitive assessments provide for identifying those at high risk for cognitive decline. We analyzed >500 ADNI participants who underwent a brief digital cognitive assessment and amyloid/tau PET scans, examining their ability to distinguish cognitive status and predict cognitive decline. Performance on the digital cognitive assessment were superior to both cortical amyloid and entorhinal tau in detecting mild cognitive impairment and future cognitive decline, with mnemonic discrimination deficits emerging as the most critical measure for predicting decline and future tau accumulation. Digital assessments are effective in identifying at-risk individuals, supporting their utility as low-burden tools for early Alzheimer's detection and monitoring.

Neuroscience
Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment

Amir H. Meghdadi,Marija Stevanović Karić,Marissa McConnell,Greg Rupp,Christian Richard,Joanne Hamilton,David Salat,Chris Berka

DOI: https://doi.org/10.1371/journal.pone.0244180

IF: 3.7

2021-02-05

PLoS ONE

Abstract:In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18–40 (n = 129), 40–60 (n = 62) and 60–90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands’ power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.

multidisciplinary sciences
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

Bernard J. Hanseeuw,Rebecca A. Betensky,Heidi I. L. Jacobs,Aaron P. Schultz,Jorge Sepulcre,J. Alex Becker,Danielle M. Orozco Cosio,Michelle Farrell,Yakeel T. Quiroz,Elizabeth C. Mormino,Rachel F. Buckley,Kathryn V. Papp,Rebecca A. Amariglio,Ilse Dewachter,Adrian Ivanoiu,Willem Huijbers,Trey Hedden,Gad A. Marshall,Jasmeer P. Chhatwal,Dorene M. Rentz,Reisa A. Sperling,Keith Johnson

DOI: https://doi.org/10.1001/jamaneurol.2019.1424

IF: 29.907

2019-08-01

JAMA Neurology

Abstract:<h3>Importance</h3><p>Positron emission tomography (PET) imaging now allows in vivo visualization of both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau neurofibrillary tangles. Observing their progressive accumulation in the brains of clinically normal older adults is critically important to understand the pathophysiologic cascade leading to AD and to inform the choice of outcome measures in prevention trials.</p><h3>Objective</h3><p>To assess the associations among Aβ, tau, and cognition, measured during different observation periods for 7 years.</p><h3>Design, Setting, and Participants</h3><p>Prospective cohort study conducted between 2010 and 2017 at the Harvard Aging Brain Study, Boston, Massachusetts. The study enrolled 279 clinically normal participants. An additional 90 individuals were approached but declined the study or did not meet the inclusion criteria. In this report, we analyzed data from 60 participants who had multiple Aβ and tau PET observations available on October 31, 2017.</p><h3>Main Outcomes and Measures</h3><p>A median of 3 Pittsburgh compound B–PET (Aβ, 2010-2017) and 2 flortaucipir-PET (tau, 2013-2017) images were collected. We used initial PET and slope data, assessing the rates of change in Aβ and tau, to measure cognitive changes. Cognition was evaluated annually using the Preclinical Alzheimer Cognitive Composite (2010-2017). Annual consensus meetings evaluated progression to mild cognitive impairment.</p><h3>Results</h3><p>Of the 60 participants, 35 were women (58%) and 25 were men (42%); median age at inclusion was 73 years (range, 65-85 years). Seventeen participants (28%) exhibited an initial high Aβ burden. An antecedent rise in Aβ was associated with subsequent changes in tau (1.07 flortaucipir standardized uptake value ratios [SUVr]/PiB-SUVr; 95% CI, 0.13-3.46;<i>P</i> = .02). Tau changes were associated with cognitive changes (−3.28<i>z</i>scores/SUVR; 95% CI, −6.67 to −0.91;<i>P</i> = .001), covarying baseline Aβ and tau. Tau changes were greater in the participants who progressed to mild cognitive impairment (n = 6) than in those who did not (n = 11; 0.05 SUVr per year; 95% CI, 0.03-0.07;<i>P</i> = .001). A serial mediation model demonstrated that the association between initial Aβ and final cognition, measured 7 years later, was mediated by successive changes in Aβ and tau.</p><h3>Conclusions and Relevance</h3><p>We identified sequential changes in normal older adults, from Aβ to tau to cognition, after which the participants with high Aβ with greater tau increase met clinical criteria for mild cognitive impairment. These findings highlight the importance of repeated tau-PET observations to track disease progression and the importance of repeated amyloid-PET observations to detect the earliest AD pathologic changes.</p>

medicine, general & internal
Smartphone‐based long‐term delayed memory performance is associated with the Preclinical Alzheimer’s Cognitive Composite and CSF levels of β‐amyloid

Fredrik Öhman,David Berron,Johan Skoog,Timothy Hadarsson Bodin,Silke Kern,Anna Zettergren,Kathryn V. Papp,Henrik Zetterberg,Kaj Blennow,Ingmar Skoog,Michael Schöll

DOI: https://doi.org/10.1002/alz.067920

2022-12-01

Abstract:Remote and unsupervised cognitive testing using smartphones may improve sensitivity to detect preclinical Alzheimer’s disease (AD). In particular, cognitive testing at‐home enables the evaluation of the potentially more sensitive long‐term delayed memory retrieval, which is commonly not feasible in a clinical setting. Here, we investigated the association between remote and unsupervised smartphone‐based cognitive assessments and in‐clinic cognitive measurement in older participants (CDR = 0, MMSE = 29.2, age = 77). The sample (non‐demented at age 70) was derived from the Swedish population‐based Gothenburg H70 Birth Cohort Studies. In a subsample of participants, the retrospective correlation with cerebrospinal fluid (CSF) biomarkers analyzed at age 70 was further explored. To this point, 177 H70‐participants have consented and were enrolled into the smartphone sub‐study. They completed an “Object‐in‐Room Recall Test“ (ORR) remotely and unsupervised using own mobile devices, and the recall session was initiated 24 hours after the initial learning phase. Available previously assessed CSF measures included the Aβ42/Aβ40‐ratio, t‐tau, p‐tau, neurofilament light (NFL), and neurogranin, available in‐clinic cognitive tests included the Rey Auditory Verbal Learning Test (RAVLT), Semantic Fluency, Digit‐Symbol‐Coding, and Mini Mental State Examination. The above‐mentioned cognitive tests were used to derive the Preclinical Alzheimer’s Cognitive Composite (PACC5), a composite designed to be sensitive to cognitive change in preclinical AD. All associations were examined using Pearson correlation coefficient. Preliminary analyses in a subset of participants yielded relatively strong positive correlations between PACC5 (R = .50, p<.001) and the ORR Long‐term Delayed Retrieval. The strongest correlation for an individual test was observed between the RAVLT Delayed Retrieval and the ORR Long‐term Delayed Retrieval (R = .52, p<.001). Regarding the CSF biomarkers, Aβ42/Aβ40‐ratio at age 70 was positively correlated with the ORR Long‐term Delayed Retrieval at age 77 (R = .43, p<.01), while measures of t‐tau, p‐tau, NFL, and neurogranin at age 70 were not. Our findings demonstrate the potential of smartphone‐based cognitive assessment to detect features of preclinical AD in a population‐based sample of older adults. Future analyses will address the relationship between these novel cognitive measures in relation to longitudinal CSF‐ and neuroimaging‐based biomarkers and clinical progression.

clinical neurology
Simplifying Alzheimer's Disease Monitoring: A Novel Machine-Learning Approach to Estimate the Clinical Dementia Rating Sum of Box Changes Using the Mini-Mental State Examination and Functional Activities Questionnaire

Kenichiro Sato,Yoshiki Niimi,Ryoko Ihara,Kazushi Suzuki,Atsushi Iwata,Takeshi Iwatsubo,Alzheimer's Disease Neuroimaging Initiative,Japanese Alzheimer's Disease Neuroimaging Initiative

DOI: https://doi.org/10.3233/jad-231426

2024-05-15

Journal of Alzheimer s Disease

Abstract:Background: Primary outcome measure in the clinical trials of disease modifying therapy (DMT) drugs for Alzheimer's disease (AD) has often been evaluated by Clinical Dementia Rating sum of boxes (CDRSB). However, CDR testing requires specialized training and 30–50 minutes to complete, not being suitable for daily clinical practice. Objective: Herein, we proposed a machine-learning method to estimate CDRSB changes using simpler cognitive/functional batteries (Mini-Mental State Examination [MMSE] and Functional Activities Questionnaire [FAQ]), to replace CDR testing. Methods: Baseline data from 944 ADNI and 171 J-ADNI amyloid-positive participants were used to build machine-learning models predicting annualized CDRSB changes between visits, based on MMSE and FAQ scores. Prediction performance was evaluated with mean absolute error (MAE) and R2 comparing predicted to actual rmDeltaCDRSB/rmDeltayear. We further assessed whether decline in cognitive function surpassing particular thresholds could be identified using the predicted rmDeltaCDRSB/rmDeltayear. RESULTS: The models achieved the minimum required prediction errors (MAE 0.5) for mild cognitive impairment (MCI) patients for changes in CDRSB over periods of 18 months or longer. Predictions of annualized CDRSB progression>0.5, >1.0, or >1.5 demonstrated a consistent performance (i.e., Matthews correlation coefficient>0.5). These results were largely replicated in the J-ADNI case predictions. CONCLUSIONS: Our method effectively predicted MCI patient deterioration in the CDRSB based solely on MMSE and FAQ scores. It may aid routine practice for disease-modifying therapy drug efficacy evaluation, without necessitating CDR testing at every visit.

neurosciences
Comparison of brief olfactory and cognitive assessments to neuroimaging biomarkers in the prediction of cognitive decline and dementia in the MCSA cohort

Davangere P. Devanand,Seonjoo Lee,José A. Luchsinger,David Knopman,Maria Vassilaki,Jeffrey N. Motter

DOI: https://doi.org/10.1002/alz.14261

2024-10-12

Alzheimer s & Dementia

Abstract:INTRODUCTION We evaluated impaired odor identification and global cognition as simple, cost‐effective alternatives to neuroimaging biomarkers to predict cognitive decline and dementia in the Mayo Clinic Study of Aging. METHODS Six hundred forty‐seven participants (mean 8.1, standard deviation 3.4 years' follow‐up) had the following baseline procedures: modified Blessed Information Memory Concentration Test (BIMCT), 12‐item Brief Smell Identification Test (BSIT), structural brain magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging with 11C‐Pittsburgh compound B (11C‐PiB) and fluorodeoxyglucose (FDG; subset). RESULTS Cognitive decline developed in 102 participants and dementia in 34 participants. In survival analyses, PiB PET showed robust prediction for cognitive decline. Impaired BSIT, impaired BIMCT, MRI, and FDG measures were also significant predictors. The combination of demographics + BSIT + BIMCT showed strong predictive utility (C‐index 0.81), similar to demographics + PiB PET (C‐index 0.80). Similar but stronger results were obtained for prediction of dementia. DISCUSSION Impairment in both odor identification test and global cognition was comparable to PiB PET for predicting cognitive decline and dementia. Highlights In 647 participants in the population‐based Mayo Clinic Study of Aging, several clinical markers and biomarkers each predicted cognitive decline or dementia during an average 8 years of follow‐up. The combination of the demographic variables of age, sex, and education with a brief odor identification test (BSIT) and a global cognitive test (Blessed Information Memory Concentration Test) showed strong predictive utility (C‐index 0.81) for cognitive decline that was similar to the demographic variables combined with Pittsburgh Compound B amyloid imaging (C‐index 0.80). Combining a brief odor identification test with a brief cognitive test needs consideration as a simple, cost‐effective option in the clinical assessment of individuals at risk of cognitive decline and dementia, as well as a potential tool to identify individuals who may benefit from disease‐modifying treatments and to screen participants for prevention trials.

clinical neurology
Redox potential of quinones in photosynthetic reaction centers from Rhodobacter sphaeroides: dependence on protonation of Glu-L212 and Asp-L213.

Hiroshi Ishikita,G. Morra,E. Knapp

DOI: https://doi.org/10.1021/BI026781T

IF: 3.321

2003-04-08

Biochemistry

Abstract:The absolute values of the one-electron redox potentials of the two quinones (Q(A) and Q(B)) in bacterial photosynthetic reaction centers from Rhodobacter sphaeroides were calculated by evaluating the electrostatic energies from the solution of the linearized Poisson-Boltzmann equation at pH 7.0. The redox potential for Q(A) was calculated to be between -173 and -160 mV, which is close to the lowest measured values that are assumed to refer to nonequilibrated protonation patterns in the redox state Q(A)(-). The redox potential of quinone Q(B) is found to be about 160-220 mV larger for the light-exposed than for the dark-adapted structure. These values of the redox potentials are obtained if Asp-L213 is nearly protonated (probability 0.75-1.0) before and after electron transfer from Q(A) to Q(B), while Glu-L212 is partially protonated (probability 0.6) in the initial state Q(A)(-)Q(B)(0) and fully protonated in the final state Q(A)(0)Q(B)(-). Conversely, if the charge state of the quinones is varied from Q(A)(-)Q(B)(0) to Q(A)(0)Q(B)(-) corresponding to the electron transfer from Q(A) to Q(B), Asp-L213 remains protonated, while Glu-L212 changes its protonation state from 0.15 H(+) to fully protonated. In agreement with results from FTIR spectra, there is proton uptake at Glu-L212 going along with the electron transfer, whereas Asp-L213 does not change its protonation state. However, in our simulations Asp-L213 is considered to be protonated rather than ionized as deduced from FTIR spectra. The calculated redox potential of Q(A) shows little dependence on the charge state of Asp-L213, which is due to a strong coupling with the protonation state of Asp-M17 but increases by 50 mV if Glu-L212 changes from the ionized to the protonated charge state. Both are in agreement with fluorescence measurements observing the decay of SP(+)Q(A)(-) in a wide pH regime. The computed difference in redox potential of Q(B) in the light-exposed and dark-adapted structure was traced back to the hydrogen bond of Q(B) with His-L190 that is lost in the dark-adapted structure and the charge of the non-heme iron atom, which is closer to Q(B) in the light-exposed than in the dark-adapted structure.

[Fluorescein angiography in diabetic retinopathy (author's transl)].

Usability of the Mayo Test Drive remote self-administered web-based cognitive screening battery in adults ages 35 to 100 with and without cognitive impairment

The development and validation of a digital biomarker for remote assessment of Alzheimer's diseases risk

Examining a Preclinical Alzheimer's Cognitive Composite for Telehealth Administration for Reliability Between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers

98 Remote App-Based Assessment of Memory and Executive Functioning in Aging and Pre-Clinical Alzheimer’s Disease

Seeing beyond the symptoms: biomarkers and brain regions linked to cognitive decline in Alzheimer's disease

Validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study

Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease

Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers

Digital cognitive assessments as low‐burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum

Association between a computerized, self-administered cognitive assessment and phosphorylated Tau in Alzheimer's Disease

Performance and validation of a digital memory test across the Alzheimer's Disease continuum

Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer's disease

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum

Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

Smartphone‐based long‐term delayed memory performance is associated with the Preclinical Alzheimer’s Cognitive Composite and CSF levels of β‐amyloid

Simplifying Alzheimer's Disease Monitoring: A Novel Machine-Learning Approach to Estimate the Clinical Dementia Rating Sum of Box Changes Using the Mini-Mental State Examination and Functional Activities Questionnaire

Comparison of brief olfactory and cognitive assessments to neuroimaging biomarkers in the prediction of cognitive decline and dementia in the MCSA cohort

Redox potential of quinones in photosynthetic reaction centers from Rhodobacter sphaeroides: dependence on protonation of Glu-L212 and Asp-L213.